v3.26.3
Note 16 - Geographic and Segment Information - Profit and Loss Information by Reportable Segment (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Total revenue $ 56 $ 15 $ 161 $ 123
Cost of revenue 16 0 52 20
Research and development 4,447 3,513 8,247 8,508
Depreciation 349 365 1,057 1,135
Total stock-based compensation 1,079 1,703 3,431 [1] 5,017
Segment loss from operations (6,347) (5,648) (13,755) (15,588)
Research and Development [Member]        
Depreciation 333 337 1,007 1,012
Total stock-based compensation 524 754 1,764 [1] 2,300
General and Administrative [Member]        
Depreciation 16 28 50 123
Total stock-based compensation 555 949 1,667 [1] 2,717
Operating Segments [Member]        
Total revenue 56 15 161 123
Cost of revenue 16 0 52 20
Segment loss from operations (6,347) (5,648) (13,755) (15,588)
Operating Segments [Member] | Research and Development [Member]        
Facilities 423 436 1,207 1,241
Depreciation 333 337 1,007 1,012
Manufacturing 776 363 931 633
Research 3 1 13 8
Equipment 40 30 124 58
Maintenance 69 53 118 117
Information technology 102 68 245 187
Personnel 2,201 1,945 6,412 6,205
Total stock-based compensation 524 754 1,764 2,300
Grant revenue as a reduction of research and development expense (2,107) (2,270) (8,021) (8,495)
Other segment items - Research and development [2] 29 13 62 117
Operating Segments [Member] | General and Administrative [Member]        
Facilities 31 29 94 90
Depreciation 16 28 50 123
Information technology 38 27 100 123
Total stock-based compensation 555 949 1,667 2,717
Grant revenue as a reduction of research and development expense (116) (130) (445) (358)
Insurance 158 182 486 544
Legal 37 70 232 393
Finance and accounting 226 270 714 800
Public and investor relations 80 63 282 293
Personnel 837 569 2,254 2,189
Other segment items - General and administrative [3] 78 93 183 269
Operating Segments [Member] | CNM-Au8, Amyotrophic Lateral Sclerosis [Member]        
Research and development 1,509 1,775 3,045 4,586
Operating Segments [Member] | CNM-Au8, Multiple Sclerosis [Member]        
Research and development 45 41 152 230
Operating Segments [Member] | CNM-Au8, Regulatory Activities [Member]        
Research and development 483 75 1,050 335
Operating Segments [Member] | General, Preclinical, Nonclinical [Member]        
General/preclinical/nonclinical 17 (108) 138 (26)
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]        
Segment loss from operations $ 0 $ 0 $ 0 $ 0
[1] Excludes $1.1 million of stock options issued to pay deferred employee compensation recorded in accrued liabilities.
[2] Includes expenses for travel, meals, dues, subscriptions, continuing education, and other miscellaneous expenses.
[3] Includes expenses for travel, meals, dues, subscriptions, continuing education, lobbying, banking fees, postage, and other office and miscellaneous expenses.